[ Price : $8.95]
FDA approves a Guerbet NDA for Elucirem (gadopiclenol), a new macrocyclic gadolinium-based contrast agent for use in contrast-enha...[ Price : $8.95]
FDA issues contract manufacturer Catalent a 12-item Form FDA-483 over GMP concerns found during a recent inspection at the firms B...[ Price : $8.95]
Harvard Medical School researchers call for a reinvigoration of the Park doctrine holding corporate officers personally liable for...[ Price : $8.95]
FDA warns Scottsdale, AZ-based BioLab Sciences it is illegally marketing drug and biologic products that have been produced with s...[ Price : $8.95]
FDA medical reviewers tell the Oncologic Drugs Advisory Committee there are significant questions about Spectrum Pharmaceuticals p...[ Price : $8.95]
FDA reviewers say that a confirmatory trial has not confirmed the clinical benefit of Oncopeptides Pepaxto (melphalan flufenamide)...[ Price : $8.95]
The Alliance for Regenerative Medicine and Pfizer suggest changes to an FDA draft guidance on real-time oncology review.[ Price : $8.95]
CDER Office of Generic Drugs associate director Sarah Ibrahim discusses the first-year output of the new Generic Drug Cluster invo...